- Home
- CLMB vs AKBA Comparison
CLMB vs AKBA Comparison
Compare CLMB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLMB
- AKBA
- Stock Information
- Founded
- CLMB 1982
- AKBA 2007
- Country
- CLMB United States
- AKBA United States
- Employees
- CLMB N/A
- AKBA N/A
- Industry
- CLMB Retail: Computer Software & Peripheral Equipment
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CLMB Technology
- AKBA Health Care
- Exchange
- CLMB Nasdaq
- AKBA Nasdaq
- Market Cap
- CLMB 417.8M
- AKBA 336.2M
- IPO Year
- CLMB N/A
- AKBA 2014
- Fundamental
- Price
- CLMB $130.17
- AKBA $2.07
- Analyst Decision
- CLMB Buy
- AKBA Strong Buy
- Analyst Count
- CLMB 1
- AKBA 1
- Target Price
- CLMB $136.00
- AKBA $7.50
- AVG Volume (30 Days)
- CLMB 29.7K
- AKBA 2.4M
- Earning Date
- CLMB 02-26-2025
- AKBA 03-13-2025
- Dividend Yield
- CLMB 0.52%
- AKBA N/A
- EPS Growth
- CLMB 39.90
- AKBA N/A
- EPS
- CLMB 3.68
- AKBA N/A
- Revenue
- CLMB $410,631,000.00
- AKBA $169,879,000.00
- Revenue This Year
- CLMB $21.18
- AKBA N/A
- Revenue Next Year
- CLMB $16.80
- AKBA $30.85
- P/E Ratio
- CLMB $35.33
- AKBA N/A
- Revenue Growth
- CLMB 22.89
- AKBA N/A
- 52 Week Low
- CLMB $49.70
- AKBA $0.80
- 52 Week High
- CLMB $142.50
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- CLMB 55.87
- AKBA 63.74
- Support Level
- CLMB $120.71
- AKBA $1.72
- Resistance Level
- CLMB $131.60
- AKBA $2.00
- Average True Range (ATR)
- CLMB 4.88
- AKBA 0.09
- MACD
- CLMB 0.27
- AKBA 0.02
- Stochastic Oscillator
- CLMB 80.22
- AKBA 94.67
About CLMB Climb Global Solutions Inc.
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The Company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.